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ABSTRACT 
 
BACKGROUND 
  Fragmented QRS complex in an ECG is a marker of myocardial 
necrosis or scarring. 
OBJECTIVE 
  To find the relationship between fragmented QRS in an ECG in the 
setting of acute ST elevation myocardial infarction and left ventricular ejection 
fraction. 
MATERIALS AND METHODS 
  Consecutive patients with acute ST elevation MI admitted in the 
intensive coronary care unit will be included in the study. The data of each 
patient is collected in a specifically prepared proforma and includes relevant 
medical history, ECG findings on admission and serial ECGs, and Ejection 
fraction assessed by Echocardiogram within 48 hours of onset of symptoms. 
Patients with fQRS in the ECG were taken as cases and patients without fQRS. 
Using statistical methods ejection fraction between the two groups was 
analysed. 
 
 
RESULTS 
  Analysis  showed that the mean ejection fraction of the cases group 
is 40.95 %.Mean ejection fraction  of the control group is 54.06 %. p value is < 
0.001**.So there is significant statistical relationship between the presence of 
fragmented QRS and the ejection fraction. 
CONCLUSION 
  There is an significant association between presence of fragmented 
QRS and the ejection fraction in the setting acute ST elevation myocardial 
infarction. Presence of fQRS indicates myocardial necrosis and hence lower 
ejection fraction when compared with controls. Hence fQRS indicates severity 
and poorer prognosis. 
KEYWORDS: FRAGMENTED QRS, EJECTION FRACTION. 
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INTRODUCTION 
 
 
Acute coronary syndromes including ST elevation MI /Non ST 
elevation MI/Unstable angina is now considered as an emerging and 
important health  problem for individuals and society. Acute Myocardial 
Infarction is the leading cause of death and also leading cause of 
hospitalization causing disability followed by malignancy and stroke. 
With the advent of promising therapies, acute myocardial infarction has a 
higher life expectancy, chance for rapid recovery and good promising 
outcomes. 
Despite new therapies, poor outcome may still occur because 
Acute  Coronary  Syndrome is a heterogeneous disease in which outcome 
is influenced by many causative factors. The extent of myocardial injury 
and the resultant outcome from ischemia is largely dependent upon the 
physiological level by the severity and duration of the ischemia. 
The risk factors namelysmoking, diabetes, dyslipidemia, blood 
pressure (BP) and alcohol predict the happening of acute coronary 
syndromes. Post ACS individual, way of living depends upon the area of 
the involved myocardium and the secondary prevention of recurrent 
cardiovascular events.    
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Notching of QRS complex is poorly understood and are under 
estimated finding in an electrocardiogram. Various studies have shown 
the relation between the fragmented QRS in an ECG following acute 
coronary syndromes and mortality and morbidity post ACS. In this study 
the relation between the presence and absence of fragmented QRS and 
the  left ventricular ejection fraction ,following an acute ST elevation 
myocardial infarction is studied .   
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REVIEW OF LITERATURE 
 
 
 
EPIDEMIOLOGY OF CADIN INDIA 
Coronary artery disease is the leading cause of death emerging in India 
and worldwide.It was thought previously that it is more prevalent in 
developed countries but it now leads to more mortality in developing 
countries like India.The rates are increasing disproportionately when 
compared to developed countries.It has a greater impact on a countries 
socio economic development(1). 
 
PREVALENCE OF CAD INDIA [2007 ESTIMATES] 
FIGURE SHOWING URBAN PREVALENCE OF CAD. 
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           FIGURE SHOWING RURAL PREVALENCE OF CAD 
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TABLE  SHOWING BURDEN OF CAD IN WORLD AND INDIA 
 
 
 
ACUTE CORONARY SYNDROMES 
Spectrum of acute coronary syndromes include 
1)UNSTABLE ANGINA 
2)NON ST ELEVATION MI 
3)ST ELEVATION MI 
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 Stable angina is characterised by chest pain or discomfort 
associated with physical exertion, which is relieved by rest or nitrates 
within 5 to 10 minutes. 
Unstable angina is defined as anginal pain atleast with 1 out of 3 
features 
1) Pain even at rest or with minimal exertion,lasting>10 minutes 
2) New onset and severe (within prior 4-6 weeks) 
3) Crescendo pattern 
NSTEMI is diagnosed if patients have clinical features of unstable 
angina with elevated cardiac biomarkers. 
In STEMI  patient presents with typical anginal pain and  has ST 
elevation in 12 lead ECG and raised cardiac biomarkers(2). 
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PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES 
 
The evolution of ACS has been shown to involve two distinct 
processes 
1) a fixed, irreversible process involving gradual narrowing of 
lumen(atherosclerosis) 
2) a dynamic, reversible process, in which there is slow progression to 
sudden and rapid coronary occlusion(thrombosis). 
FIGURE: PROCESS OF THROMBUS FORMATION INVOLVING 
PLATELET ADHESION, ACTIVATION AND AGGREGATION 
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In many situations atherosclerosis predominates in chronic stable 
angina and thrombosis predominates in ACS(3). Hence the term 
atherothrombosis is used frequently. 
 
ATHEROSCLEROSIS 
Endothelial dysfunction is the initial triggering part of 
atherosclerosis.Endothelial dysfunction or injury triggers various 
cytokine,growth factors,hydrolytic enzymes with focal vessel wall 
necrosis and tissue repair and fibrosis ,simultaneously. 
The next stage is the formation of fibrofatty plaque.The plaque 
consists of a raised lesion with soft,yellow core which consist of lipid 
(cholesterol and its esters) and covered by a firm, white fibrous cap(4). 
This cause obstruction to blood flow, and also weaken the underlying 
media and when it ruptures, causes acute thrombosis of the vascular 
lumen. 
 
PLAQUE STABILTY 
It is dependent on three factors: 
A) Mechanical stress acting on fibrous cap 
B) Factors causing weakening of the cap 
C) Inflammatory triggers. 
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FIGURE : PLAQUE STABILITY 
 
          A plaque becomes ‘unstable’ or ‘vulnerable’ when the balance 
between the production and destruction(5) of interstitial collagen,is 
disrupted.  
FIGURE: PLAQUE STABILITY 
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RISK FACTORS FOR ATHEROSCLEROSIS 
TABLE: MAJOR RISKS FACTORS 
 
NON MODIFIABLE RISK FACTORS 
Age 
It has a greater influence in the pathogenesis of atherosclerosis. 
The accumulation of atherosclerotic plaque is a gradual process, it does 
not clinically manifest until it reaches a critical threshold.The incidence 
of myocardial infarction in men increases by five times by the age of 40-
60, even though the underlying lesions were evolving before that. 
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Gender 
After menopausal age, the incidence of atherosclerosis-related 
diseases in women is more than that of men. Premenopausal women are  
protected against atherosclerosis and its complications if compared to 
men of same age. This is explained by favourable influence of oestrogen 
on atherosclerotic process(6).This explains why complications of 
atherosclerosis like MI and stroke are uncommon in premenopausal 
women unless they have other risk factorslike dyslipidemia,systemic 
hypertension or diabetes.  
 
Genetic factors 
The familial tendency for atherosclerosis and coronary artery 
disease is a well-known fact and it is influenced by several factors. In few 
instances it is due to presence of other risk factors like systemic 
hypertension or diabetes in the same family(7).Whereas in others it 
involves a well-defined genetic derangements in lipid metabolism, such 
as familial hypercholesterolemia. 
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MODIFIABLE RISK FACTORS 
Hyperlipidemia 
This is a well-known major risk factor for atherosclerosis.Even in 
the absence of other risk factors, dyslipidemia by itself can cause 
atherosclerosis development(8). The most important lipid component in 
blood associated with coronary artery disease is lowdensity lipoprotein 
(LDL) cholesterol .Its major function is to deliver cholesterol to 
peripheral tissue. In contrast, highdensity lipoprotein [HDL] mobilizes 
cholesterol from atheromas and transports it to the liver after which it is 
excreted into the bile. Hence higher is the serum HDLlevel, lesser is the 
cardiovascular risk. 
Diet and pharmacotherapy which lower LDL or and raise serum 
HDL are all of high interest. Increased intake of animal fats,butter and 
egg raises serum cholesterol levels. On the other hand diets low in 
cholesterol and with higher ratios of PUFA (polyunsaturated fatty acids) 
lowers plasma cholesterol levels. Omega-3 fatty acids are beneficial(9), 
whereas unsaturated fats which are produced by hydrogenation of 
polyunsaturated oils produce an negative impact on cholesterol 
profiles.Aerobic exercises and moderate intake of alcohol raise HDL 
levels, whereas obesity and smoking decreases it.  
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HYPERTENSION 
       Another major important risk factor which is associated 
atherosclerosis is hypertension; systolic and diastolic blood pressures are 
equally important. Coronary artery disease risk increases by 
approximately60% in hypertensive patients when compared to 
populations with normal blood pressure. When hypertensive patient is not 
treated approximately half of patients will die of CAD or congestive 
cardiac failure, and another third will die with the development of stroke. 
 
CIGARETTE SMOKING 
Cigarette smoking is associated with increased risk in both sexes. 
Daily smoking of more than 1 pack of cigarettes increases the death rate 
from CAD by 200%. When it is stopped the risk is 
reduceddramatically(10). 
 
DIABETES MELLITUS 
Diabetes acceleratesdyslipidaemia and atherosclerosis occurs more 
frequently. The risk of acquiring acute myocardial infarction is twice in 
diabetics as compared to nondiabetics. 
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ATHEROSCLEROSIS OF CORONARY ARTERIES 
Atherosclerotic activity occurs mainly in large vessels like 
epicardial coronary artery. The factors associated with atherosclerosis 
viz. increased plasma low density lipoprotein(LDL) , decreased serum 
highdensity lipoprotein(HDL), smoking,systemic hypertension, and 
diabetes mellitus interferes with the functions of the vascular lumen 
endothelium which include a)control of local vessel tone b)maintaining 
antithrombotic state over the surfaceand c) control of inflammatory cell 
adhesion and diapedesis(11).  
When these properties are impaired it results in pathologic 
occlusion, thrombus formation, and abnormal interactions among blood 
cells(WBC,RBC,PLATLETS), most importantly between macrophages 
and platelets and the activated luminal endothelial cells. These are the 
functional changes and they lead to the subintimal collections of lipids, 
intercellular matrix, smooth muscle cells and fibroblasts that result in the 
formation of atheroma.  
There is an increased tendency for atherosclerotic plaques to form 
at sites where there is increased turbulent flow in coronary arteries, 
commonly at branchingpoints in the epicardialarteries(12).  
When luminal diameter is reduced to50% of an epicardial 
arterydiameter, ability to increase coronary flow is limited when 
myocardial demand is more. When the diameter is reduced by 
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80%approximately,even during period of rest, blood flow may be reduced 
, and further small decreasein the stenosed vessel orifice area can 
decrease coronary flow markedly and cause myocardial infarction or 
ischemia at rest or only with minimal exercise. 
Narrowing of epicardial coronary artery by atherosclerosis in most 
of case is caused by the formation of a plaque, which can leads to rupture 
or erosion of the cap and this separates plaque from the bloodstream.  
When plaque contents is exposed two important and related 
processes occurs: (a) platelets activation and aggregation, and (b) the 
coagulation process is activated, which results in deposition of fibrin 
strands . The thrombus consist mainly platelet aggregates and fibrin 
strands along with red blood cells and it can reduce coronary blood flow, 
resulting in the clinical manifestations of myocardial ischemia. 
The thrombuslocation determines the quantity of myocardial cells 
that become ischemic and play a main role indetermining the severity of 
the clinical features(13). So, critical obstructions narrowing diameter of  
maincoronary vessels, such as the left main coronary artery(LMCA) and 
the proximal portion of left anterior descending (LAD) coronary artery, 
are associated with poorer outcomes(14). Chronic severe narrowing of 
coronary vessel leading to myocardial ischemia ultimately result in the 
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development of collateral blood vessels, particularly when there is 
gradual development ofnarrowing . When collaterals arewell developed, 
they alone can provide sufficient amount of blood flow and sustain the 
viability of the myocardium at rest but not during time of increased 
demand like exercise . 
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HISTORY AND CLINICAL PRESENTATION 
Pain in the left retrosternal region or discomfort in the epigastric 
region are the most common presentationin patient with acute coronary 
syndrome, and frequently radiates to the neck, left shoulder,right 
shoulder, back but more commonly to the left shoulder and arm. 
Thisdiscomfort is usually very severe, compressing nature and may be 
experienced as frank pain.  
“Anginal equivalents" are the features other than chest pain in a 
patient with CAD can present,such as breathlessness and discomfort in 
epigastric region, and these occur more frequently in females and 
diabetics(15).The physical examination is very similar to that seen in 
patients with stable angina and sometimes not well prominentat all. If the 
patient is affected by severe myocardial ischemiaor extensive 
UA/NSTEMI, the clinical features like diaphoresis, pale and cold 
peripheries, tachycardia, gallop rhythm, pulmonary crepitations and 
shock, similar to the features seen in patients with ST elevation can be 
seen . 
While evaluation of patients with suspected STEMI/UA/NSTEMI 
is made ,one should keep in mind ,whether the chest discomfort of being 
caused by myocardial ischemia can be in one of three categories: high, 
intermediate, or low likelihood(16). 
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TABLE : CATEGORIES OF MYOCARDIAL ISCHEMIA 
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TABLE: KILLIP’SCLASSIFICATION OF PATIENTS WITH ACUTE 
MI. 
 
 
ELECTROCARDIOGRAPHY 
The presence or absence of MI and prognostication can be done by 
a simple 12 lead ECG.A first ECG within 10 minutes of arrival to the 
casualty is the protocol. ECG changes in T-wave are sensitive for 
myocardial ischemia but are specific, only when they are new, deeper and 
magnitude of T wave inversions ≥ 0.3millivolt.Continuous ECG 
monitoring is recommended as periodic ECG may not accurately reflect 
the dynamicity(17).                                                                            
STEMI is defined by ST segment elevation greater than 2mm  in 2 
or more contiguous precordial leads or more than 1mm in 2 or more 
contiguous limb leadsor new onset left bundle branch block. 
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TABLE : LOCALISATION OF MI AND ITS SPECIFIC 
COMPLICATION 
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CARDIAC BIOMARKERS 
The first cardiac biomarker identified was SGOT or  AST.Soon 
LDH and CK MB came into light.Patients who has 
unstableangina/NSTEMI and have elevated cardiac enzymes indicating 
myocardial necrosis, such as Troponin and CPK-MB , and are at 
increased risk for death or recurrent MI(18). When levels of these cardiac 
bio markers increase it helps to differentiate patients with NSTEMI and 
UA. 
More is the level of troponin more is the increase and death 
rate.False positive  minor elevations in troponins have been seen in 
patients without myocardial necrosis and is be due to congestive heart 
failure, myocarditis,chronic kidney disease and pulmonary embolism(19). 
Thus, in patients without a significant history, mild elevations in troponin 
cant be used for diagnosis of myocardial necrosis. 
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ECHOCARDIOGRAPHY 
This is the most popular and widely available modality for cardiac 
imaging. Myocardial necrosis results in left ventricular regional wall 
motion abnormalities(RWMA)(20).This precedes both symptoms and ECG 
findings.It can’t distinguish between  RWMA of an old infarction and 
RWMA of acute MI.LV systolic and diastolic function can be assessed, 
which is a prognosis determinant. 
MYOCARDIAL PERFUSION IMAGING 
Lack of blood flow to the affected region can be identified by 
nuclear   perfusion scan(21). It can’t differentiate from an old infarction. 
Imaging during rest and stress is a standard procedure. 
CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY 
Coronary computed tomography angiography (CCTA) is a 
powerful tool emerging for patients with suspected ACS. Imaging can be 
done in less than 10-15 seconds(22). 
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CARDIOVASCULAR MAGNETIC RESONANCE IMAGING 
CMR has the capacity to assess perfusion,viability and cardiac 
function in the same setting.Late gadolinium enhancement allows for 
assessment of viable myocardium and infarction/scar. 
STEMI is diagnosed if patient has any two of the following. 
A].Patient with ischemic discomfort 
B]. ST elevation in electrocardiogram  
C]. Rise in serum biomarker. 
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DIFFERENTIAL DIAGNOSIS 
For patients having acute onset chest pain, consider the following 
differential diagnosis 
• Hypertensive urgency or emergency  
• GERD 
• Pericarditis 
• Myocarditis 
• Pulmonary embolism 
• Oesophageal rupture or spasm 
• Aortic dissection 
• Pneumothorax 
• Costochondritis 
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ORAL ANTI PLATELET THERAPY 
ASPIRIN 
It forms the main component in the treatment of patients with 
unstable angina/NSTEMI.It irreversibly inhibits thromboxane A2 by 
inhibiting cyclooxygenase enzyme.The common loading dose is150- 365 
mg. Low doses (75–150 mg/d) is given for long-term therapy. "Aspirin 
resistance" is encountered in5 to 10% percent of patients(23). It might 
result from inadequate dose, non compliance and poor absorption or 
rapid metabolism. 
 
CLOPIDOGREL AND TICLOPIDINE 
Both are ADP antagonists and belong to thienopyridine group 
.They reduce blood viscosity by increasing bleeding time.Clopidogrelis 
an inactive prodrug,converted into an active metabolite.When used in 
combination with aspirin,it was shown to provide a significant reduction 
in death due to MI, stroke and cardiovascular events, compared with 
aspirin alone(24). This effect is seen in both low and high risk patients. 
Disadvantage of this combination is a moderate but absolute one percent 
increase in significant bleeding episode(25).Loading dose of clopidogrel 
given is 600mg orally ,which is followed by 75 mg per day orally. 
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NEWER ANTIPLATELET DRUGS 
Prasugrel, ticagrelor, cangrelor are newly available antiplatelet 
drugs.Prasugrel has more faster antiplatelet effect and profound action 
than clopidogrel.It achieves higher levels of platelet inhibition.Ticagrelor 
is a reversible inhibitor of p2y12 receptor(26).PLATO trial compared 
efficacy of clopidogrel and ticagrelor.The main adverse effects are 
ventricular pauses and dyspnoea. 
GP llb/llla INHIBITORS 
They act by occupying llb/llla receptors on the surface of the 
platelets that are activated.Prevents formation of cross linking platelets 
from fibrinogen.Three drugs approved are abciximab,tirofiban and 
eptifibatide. 
ANTICOAGULANTS 
UNFRACTIONATED HEPARIN 
It is a time tested drug mainly used in unstable angina.One of the 
main challenge associated with heparin therapy is target level of 
anticoagulation.Activated partial thromboplastin (aPTT) is frequently 
monitored.Heparin induced thrombocytopenia (HIT) is one of the life 
threatening complication associated.It is due to formation of platelet 4 
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and heparin complex and results in disseminated intravascular 
coagulation(DIC).Lepirudin,argotroban and fondaparinux is used in 
treatment. 
LOW MOLECULAR WEIGHT HEPARIN 
Close monitoring as like with unfractionated heparin is not 
required in low molecular weight heparin.There is low incidence of HIT 
and bleeding complications(27). 
DOSAGE; 
Enoxaparin-1 mg/kg SC q12h 
Dalteparin-120iu/kg SC q12h 
GFR-10 to 50 ml/min:usual dosage 
GFR-<10 ml/min:50 % of usual dosage. 
FONDAPARINUX 
It is a synthetic pentasaccharide ,specific inhibitor of factor Xa.It 
allows a fixed dosage, simple, once a day regimen of subcutaneous route. 
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DIRECT THROMBIN INHIBITORS  
Bivalirudin is a direct thrombin inhibitor which has equal potency 
to either unfractionated heparin or low molecular weight heparin, has less 
bleeding when bivalirudin alone is used it when compared to the 
combination of UFH/LMWH and a GP IIb/IIIa antagonist in patients 
with unstable angina and non ST elevation MI undergoing catheterization 
andPCI(28). 
TABLE : ANTIPLATELETS AND ANTITHROMBOTIC AGENTS 
OVERVIEW 
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NITRATES 
This is the main stay of treatment for angina.Nitrates are converted 
to nitric oxide to cause vasodilatatation of capacitance vessels.This 
results in decreased venous return(preload) and reduction in afterload.So 
there is a reduced myocardial O2 demand and stress.Nitrates can be 
administered by sublingual route (0.3–0.6 mg)or it is given by 
buccalspray in patient experiencing chestpain(29). If patient have pain 
even after giving 3 doses given 5 minutes apart, intravenous NTG [5–10 
microgram/min] should be given. The rate of the infusion may be 
adjusted by increasing 10 microgram/min every 3 to 5 minutes till 
symptoms subsides or systolic blood pressure becomes less than 100 
mmHg.Common side effects include hypotension and headache.Absolute 
contraindication for using nitrates are hypotension and use of sildenafil 
group drugs in the previous one or two days(30). 
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BETA BLOCKERS 
Oral beta blockers comes under class l recommendation and should 
be initiated within 24 hours of admission.They act by inhibiting beta l 
adrenergic receptors.It decreases myocardial contractility,AV nodal 
Conduction and sinus nodal rate(31).It increases the duration of 
diastole,thereby increasing coronary blood flow.Target heart rate 
maintained is 50 to 60 bpm.Contraindications for its use are sinus 
bradycardia( <50 bpm),any second degree ,third degree 
block,hypotension,history of asthma/COPD.  
 
CALCIUM CHANNEL BLOCKERS 
They act by causing coronary vasodilation,decreasing heart 
rate,decreasing myocardial contractility.Drugs like diltiazem and others 
in calcium channel blockers group are used in patients who are not 
relieved of symptoms despite treatment with maximum dose ofbeta 
blockers and nitrates and in patient whom beta blocker cannot be used 
due to contraindications like asthma(32).It is also used in prinzmetal 
angina.Nifedipine is harmful in acute MI. 
 
NEWER ANTI-ISCHEMIC THERAPIES 
Ranolazine,nicorandil,ivabradine,trimetazidine. 
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TABLE : 
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THROMBOLYSIS 
It is an effective therapy in STEMI and should be given within 3 to 
6 hrs of onset of chest pain for its maximal effect . 
Class I 
1. In the absence of any contraindications, fibrinolytic drug can be given 
to ST elevation MI patients with onset of symptoms within the previous 
12 hours and has a ST elevation > than 0.1 mV in at least two contiguous 
precordial leads or at least two adjacent limb leads(33).(Level of Evidence: 
A) 
2. Thrombolytic therapy is also indicated in ST elevation MI patients 
with onset of symptoms within the prior 12 hours of admission and 
presumably new or new onset LBBB. (Level of Evidence: A)   
Class IIa 
1. When there is no any of the contraindication it is reasonable to 
administer thrombolytic therapy to STEMI patients with onset of 
symptoms within the prior 12 hours of admission and ECG  shows true 
posterior MI(34). [Level of Evidence: C] 
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2. When there is no contraindications, it is justifiable to use 
thrombolytictherapy to patients who has symptoms of ST elevation MI 
beginning within the previous 12 to 24 hours who have persistent 
ischemic symptoms and ST elevation >0.1 millivolt in at least two 
continuous precordial leads or in  two adjacent limb leads(35). [Level of 
Evidence: B] 
Class III 
1. Fibrinolytic therapy is not used in asymptomatic patients whose 
symptoms of ST elevation MI started more than 24 hours earlier(36). 
[Level of Evidence: C] 
2. Fibrinolytic therapy is not used in patients whose ECG shows except if 
a posterior wall MI is suspected ST-segment depression  or ST depression 
with ST elevation in lead avR(37). [Level of Evidence;A] 
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TABLE:  CONTRAINDICATION OF THROMBOLYTIC AGENTS 
 
 
 
 
 
36 
 
 
 
TABLE: FIBRIN SPECIFIC THROMBOLYTIC AGENTS 
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INVASIVE STRATEGIES 
 
PERCUTANEOUS CORONARY INTERVENTION 
Percutaneous coronary intervention in a setting of ST elevation of 
MI can be done by following conditions: 
-Primary PCI 
-Rescue PCI 
-Facilitated PCI 
-Early PCI 
-Delayed PCI 
 
PRIMARY PCI 
Effective reperfusion following ST elevation MI can be done by 
thrombolysis  or primary percutaneous intervention,without precedent 
thrombolysis(38).It is also known as primary angioplasty. 95 % of patients 
treated with primary PCI obtain complete perfusion ,whereas only 50 to 
60 % of patients have complete reperfusion when treated by 
thrombolysis(39) . Primary PCI has the advantage of lower risk of stroke 
and angiography, quickly defines coronary vessels anatomy. 
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RESCUE PCI 
Emergency PCI done in a patient with failed thrombolysis is called 
rescue PCI.Success of this technique in patients with moderate and large 
infarct size has been shown in terms of good LV function and 
outcomes(40). 
FIGURE:  
 
 
 
39 
 
FACILITATED PCI 
As the name indicates facilitated PCI refers to immediate 
pharmacotherapy followed by mechanical reperfusion.It leads to better 
antegrade blood flow restoration in IRA(Infarct Related 
Artery)(41).Bleeding manifestations were increased significantly in 
patients with facilitated PCI. 
 
EARLY PCI  
Primary percutaneous coronary intervention (PCI) is the preferred 
treatment for patients with STEMI(42). But only few patients can receive it 
within recommended by the guideline i.e 90 min. Early routine PCI after 
thrombolysis in STEMI patients combined lytic therapy and angioplasty, 
which provides complete,rapid and sustained reperfusion for ST elevation 
MI patients(43). 
DELAYED PCI 
PCI done after 12 hours to 3 months after thrombolysis provides 
improved LV function,provision of coronary collaterals and electrical 
stability is increased(44). 
 
40 
 
COMPLICATIONS OF ACUTE CORONARY SYNDROMES 
Most frequent complications associated are, 
-Arrythmias and conduction disturbances 
-Mechanical complications 
-Pump failure  
A) ARRYTHMIAS AND CONDUCTION DISTURBANCES 
EARLY ARRYTHMIAS: 
Ventricular arrhythmias- 
Ventricular fibrillation/tachycardia occurring early after ST 
elevation MI is associated with increased mortality in-hospital,but not 
associated with long term mortality.Early predictive marker of VF/VT are 
neither nonsustained VT nor accelerated idioventricular 
rhythm(45).Ventricular ectopics are common in ST elevation MI,but their 
predictive value for VT is undetermined. 
Supraventricular arrhythmias- 
 10 to 20% of ST elevation MI is complicated by atrial fibrillation.It 
occurs more commonly in older age patients,severe LV failure and heart 
failure(46).It is associated with increased incidence of stroke and in-
hospital mortality. 
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LATE VENTRICULAR ARRYTHMIAS: 
Ventricular arrhythmias occurring within first 24 to 48 hours have 
a low predictive value for occurrence of recurrent arrhythmias(47). 
Arrythmias occurring later have a propensity to recur,in contrast. 
 
CONDUCTION DISTURBANCES 
Most common disturbance is sinus bradycardia seen in about 9 to 
25%,especially found in inferior wall myocardial infarction. This is 
treated with injection atropine or temporary pacing if atropine fails(48). 
Persistent bundle branch blocks are seen in 5.3% of cases.AV 
blocks occurs in 7% of cases.Patients with AV block tend to have an 
extensive region of infarction.So they have a high in-hospital mortality. 
 
B) CARDIOGENIC SHOCK 
It can defined as the organ dysfunction due to hypoperfusion due 
to cardiac dysfunction .Due to inadequate cardiac output there is tissue 
hypoxia ,fluid overload and heart by itself  becomes susceptible to 
hypoperfusion(49).Progresive tissue hypoperfusion worsens ongoing 
ischemic process and contribute further in detoriation of myocardial 
function. 
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Criteria for defining cardiogenic shock 
-systolic BP <80 mm of Hg 
-persistent hypotension(atleast 30 min) 
-cardiac index <1.8L/m2/min 
-oliguria,confusion,cold extremities 
-pulmonary capillary wedge pressure >18mm of Hg(50) 
 
 
CAUSES FOR CARDIOGENIC SHOCK IN ACUTE MI 
1)Large infarction size (left main coronary artery,proximal LAD 
related   artery) 
2)Small infarct over pre existing severe LV dysfunction 
3)Acute mitral regurgitation 
4)Ventricular septal rupture 
5)Free wall rupture 
6)Pericadialtamponade 
7)Right ventricular infarct(51). 
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INVESTIGATIONS 
 
ECG 
ST elevation or depression are significant.ST elevations are useful 
in locating the culprit artery.LBBB denotes extensive anterior wall 
involvement.Low voltage complexes indicate pericardial 
effusion,massive infarction.Atrial fibrillation (AF)  is the most common 
tachyarrythmia. 
 
CHEST X RAY 
Enlarged cardiac shadow indicates previous structural heart 
disease. Normal sized heart shadow indicates newer onset cardiac 
pathology. Pulmonary congestion is present often seen pulmonary edema.   
Flask shaped heart is seen in pericardial effusion(52). 
 
ECHOCARDIOGRAPHY 
It is a valuable test in establishing cardiac cause for shock.It can 
identify LV or RV dysfunctions,valvular lesions,pericardial 
tamponade,papillary muscle dysfunction,ventricular septal rupture.TEE 
has an advantage over TTE(53). 
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PULMONARY CAPILLARY WEDGE PRESSURE 
It has a definite role in most cardiogenic shock cases.It assess the 
filling  pressure and cardiac output.It helps to differentiate between 
cardiogenic and non cardiogenic pulmonary edema. 
 
MANAGEMENT 
 
INOTROPES 
Levosimendan is a new calcium channel sensitizer which improves 
myocardial contractility,without increasing myocardial oxygen demand.It 
induces coronary and peripheral vasodilatation.Dopamine infusion is 
started at the rate of 5 to 10 microgram/kg/min. 
 
INTRA AORTIC BALLOON PUMP 
Intra aortic balloon pump (IABP) counterpulsation is in use for the 
past 30 years.It is introduced along the common femoral artery.The 
balloon is inflated with helium.It reduces the LV afterload ,in turn 
decreases the myocardial oxygen supply mismatch(54).It also increases the 
coronary blood flow during diastole. 
Complications include limb ischemia ,hypotension, bleeding, 
infection and cholesterol embolization. 
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PERCUTANEOUS CARDIOPULMONARY SUPPORT 
Whatever the underlying cardiac rhythm and cardiac function, 
percutaneous cardiopulmonary support provides cardiac support during 
PCI. This technique involves insertion of large bore cannula into the 
femoral artery and vein.Blood is collected from right atrium and 
circulated via membrane oxygenator and a heat exchanger and reinfused 
into arterial system via femoral artery. 
 
IMPELLA 2.5 SYSTEM 
Impella 2.5 system is a device placed across aortic valve.The 
device aspirates blood from left ventricular cavity and expels into the 
ascending aorta. 
 
C) MECHANICAL COMPLICATONS 
FREE WALL RUPTURE 
It can be subacute or acute.When the free wall rupture is acute ,it is 
generally fatal.It is characterized by electromechanical dissociation and 
cardiovascular collapse.Clinical features are similar to reinfartion.Has 
chest pain and ST elevation in ECG.Signs of cardiac tamponade 
occurs.ECHO shows site of free wall rupture and 
hemopericardium(pericardial space is filled with clot).Urgent surgical 
repair is the main stay of treatment. 
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VENTRICULAR SEPTAL RUPTURE 
It may occur on day one,most commonly from 3 rd to 5 thday.Most 
common in anterior wall MI.Symptoms include dyspnea and chest 
pain.There is pan systolic murmur which is loud and marked features of 
cardiogenic shock.ECHO is diagnostic and it shows left to right shunt 
across the interventricular septum(55). 
Surgery is the best option.It comprises of debridement of necrosed 
area and reconstructed with prosthesis.But prognosis is very poor.Initial 
support can be given by intra aortic balloon counter 
pulsation.Nitroprusside is given for afterload reduction(56). 
 
MITRAL REGURGITATION 
13 to 45 % of patients with STEMI are found to have mitral 
regurgitation of mild to moderate severity.Severe mitral regurgitation in 
the setting of acute MI caused by papillary muscle dysfunction accounts 
for cardiogenic shock and mortality.Other mechanisms include a) left 
ventricular dilatation b)severe RWMA(regional wall motion 
abnormalities) c)papillary muscle dysfunction due to ischemia(57). 
Inferior wall MI is most commonly associated with papillary 
muscle rupture.Large infarct is not required to produce papillary muscle 
rupture as that of free wall rupture and ventricular 
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septalrupture.Itpresents with acute severe dyspnea,pulmonary edema and 
cardiogenic shock(58).Unlike murmur of ventricular septal rupture the 
murmur of MR is soft . 
Emergency bedside ECHO is the required for diagnosing. 
Pulmonary artery catheterization demonstrates large Y waves. 
Treated by measures reducing the afterload like nitroprusside and 
IABP. Inotropes are frequently combined.Mitral valve replacement may 
be required(59). 
 
D)RIGHT VENTRICULAR INFARCTION 
Right ventricular MI with  hemodynamically significance occurs in 
inferior wall or inferoposterior wall MI(60). 
         Clinical features include 
-Elevated JVP 
-Hypotension 
-Pulsusparadoxus 
-Kussmauls sign 
-High grade AV block 
-Tricuspid regurgitation 
-Right sided s3 s4. 
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ECG shows ST elevation in V4R.It has 80% predictive 
value.ECHO shows degree of RV dysfunction and left ventricular inferior 
wall involvement.Pulmonary artery catheterization shows high right atrial 
pressure 
 
TREATMENT  
Fluid administration with hemodynamic monitoring.Central 
venous pressure is kept around 15mm Hg. Dopamine is the inotrope of 
choice as it increases the cardiac index and RV function. 
Intervention like PCI with successful reperfusion of branches 
supplying right ventricle,have improved right ventricular 
ejection.Temporary pacing and IABP may be used(61).RV assist device is 
used none of the above methods help and patient remains in shock. 
 
E) VENTRICULAR ANEURYSMS 
Acute aneurysms may be severe enough to cause congestive 
cardiac failure and cardiogenic shock.It expands during systole.Chronic 
aneurysms are the one which are present more than 6 weeks.They usually 
don’t expand during systole.  
 Persistent ST elevation >4 wks points toward LV aneurysm.Chest 
xray may show localized bulge.ECHO is the investigation of choice. True 
aneurysm have wide neck which pseudo aneurysm doesn’t have. 
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If mural thrombus is detected anti coagulation is required for 3 to 6 
months.Surgery is indicated if patients have refractory cardiac failure. 
 
F) DYNAMIC LVOT OBSTRUCTION 
Dynamic LVOT obstruction is an uncommon complication 
following an acute MI.Hyperkinesis of mid segments of LV and basal 
segment.LVOT obstruction results due to venturieffect(62). 
ECHO demonstrates hyperkinesis,systolic anterior motion of 
anterior mitral leaflet and LVOT obstruction.Beta blockers are added 
gradually.Small boluses of normal saline may decrease obstruction. 
 
 
G) DRESSLER’S SYNDROME 
 It occurs after 1 to 8 weeks after acute MI.Patients may present 
with fever,arthralgia,malaise,pleuritic chest pain,elevated ESR and 
leucocyte count.Autoimmune etiology has been postulated.ECHO shows 
pericardial effusion.It is treated by aspirin.NSAIDs and corticosteroids 
are avoided.Early pericarditis occurring within 1 to 4 days are reported in 
10%.Chest pain increases by lying down and relieved by sitting up or 
leaning forward.ECG shows generalized ST elevation.ECHO shows 
pericardial effusion.Treatment is same as that of dresslers’ssyndrome(63).   
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SECONDARY PREVENTION AFTER ACUTE CORONARY 
SYNDROME 
Primary prevention includes people with recognised risk factors 
and asymptomatic or preclinical stage of disease.Secondary prevention is 
targeted against people with established disease.The patient with an 
episode of acute MI are at very high risk of developing of another 
episode of ACS(64). 
 
CONTROL OF RISK FACTORS  
LIPIDS 
High dose of statin should be started.fibrates should be included if 
triglycerides are high. 
     GOALS: 
LDL  <70mg/dl 
HDL  >40mg/dl for men 
>50mg/dl for women 
            TG   <150mg/dl 
BLOOD PRESSURE  
It is selected by considering cardiac status 
GOAL: BP <140/85 mm of Hg. 
DIABETES 
Combination of dietary modification,physical activity,OHAs and                                                               
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insulin. 
GOAL: 
           HbA1C <7% 
DIET 
GOAL: 
            BMI               <25 
            Waist circumference  <40 inches for men 
<35 inches for women 
 
EXERCISE 
Moderate intensity exercise.Atleast 30 minutes a day ,5 days a 
week. 
SMOKING 
With or without pharmacotherapy.Behaviour modification. 
 
PHARMACOLOGIC MEASURES 
ASPIRIN 
Use of aspirin from a range of 75 to 325 mg daily found to have 
risk reduction of stroke,recurrent MI or cardiovascular death.It is 
recommended for each and every patient without 
contraindications.Aspirin desensitization should be done for patients with 
aspirin allergy.It should be started within 48 hours following CABG.For 
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patients after PCI, 1 month for bare metal stent,3 months for sirolimus 
eluting stent,6 months for paclitaxel eluting stent,aspirin is given in a 
higher dose of 325 mg/day(65). 
CLOPIDOGREL 
Clopidogrel is added to aspirin for patients after acute coronary 
syndrome and given for 12 months.Given for patients undergone PCI ,for 
atleast a month for bare metal stents and 12 months for drug eluting 
stents(66). 
BETA BLOCKERS 
Various randomized controlled trials have shown that beta blockers 
are beneficial in patients with MI ,depressed LV ejection fraction and 
heart failure.Beta blockers are continued indefinitely for patients with 
MI,left ventricular dysfunction,ACS and heart failure unless otherwise 
contraindicated. 
 
RENIN ANGIOTENSIN ALDOSTERONE INHIBITORS 
 ACE inhibitors are prescribed for ST elevation MI patients to avoid 
cardiac remodelling.They are also recommended for post ACS patients 
with diabetes,hypertension and chronic renal failure.Post ACS patients 
should not be treated with combined ACE inhibitors and ARBs(66). 
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ANTICOAGULATION POST –ACS 
Patients with left ventricular or left atrial thrombusshould be 
treated with warfarin,aspirin and clopidogrel.There is an increased risk of 
bleeding associated with use of this combination therapy.The INR is 
maintained between 2-3.It is also indicated in prosthetic valve post MI. 
 
ANTIARRYTHMIC DEVICES 
Studies have shown that selected patients post STEMI are shown 
to benefitted from implantable cardiacdevices.The recommendations for 
implantable cardiac devices are a) 40 days post MI and b) left ventricular 
EF 30 TO 35%. 
Cardiac synchronization therapy for heart failure is indicated if a) 
Left ventricular EF < 35% b) QRS duration more than 0.12 seconds c) 
patient should be in sinus rhythm(67). 
HEART FAILURE: 
Heart failure is characterized by Breathlessness, fatiguability, 
crepitations and edema. There are two types of it.  
1. Systolic failure (EF<40-50%) 
2. Diastoic failure (EF>40-50%) 
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Some causes of systolic failure 
1. Systemic hypertension 
2. Coronary artery disease 
3. Dilated cardiomyopathy 
Some causes of diastolic failure 
1. Restrictive cardiomyopathy 
2. Old age(68). 
NYHA classification of symptoms of heart failure: 
NYHA 
class 
Features  
Class I Routine activities do not cause undue fatigue, 
palpitations, dyspnea, or anginal pain. 
Class II Routine activities result in symptoms 
Class III Marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary activity causes 
symptoms. 
Class IV Symptoms of heart failure or the anginal syndrome are 
present even at rest. 
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PATHOGENESIS: 
FIGURE: 
 
Increased Aldosterone will lead to increased sodium and water 
reabsorption(69). 
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FIGURE: 
 
 
The various compensatory mechanisms include: 
1. Increased Renin-Angiotensin-Aldosterone activity 
2. Increased Sympathetic activity 
3. Increased myocardial contractility 
4. Increased vasodilatory molecules ( ANP, BNP, PGE2 and PGI2)(70). 
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As a result of these stimuli, complex events occur at the cellular 
level leading to Ventricular Remodelling(71). 
Those are 
1. Myocyte hypertrophy 
2. Myocyte loss via apoptosis, necrosis 
3. Altered contractile properties 
4. Altered myocyte metabolism 
5. Reorganized extracellular matrix 
6. Desensitization to beta adrenergic stimuli(72) 
The biochemical stimuli for such changes are: 
1. Norepinephrine 
2. Angiotensin-2 
3. Endothelin 
4. TNF 
 
All these microcellular level changes reflect on the anatomy of heart(73) as 
1. Left ventricular wall thinning 
2. Left ventricular dilation 
3. Increased roundness of left ventricle 
 
59 
 
 
Clinical features- Symptoms: 
1. Dyspnoea due to activation of pulmonary J receptors by intra-alveolar 
and interstitial accumulation of fluid(74). 
2. Orthopnea. 
3. Paroxysmal nocturnal dyspnoea 
4. Cheyne-Stokes breathing 
5. Anorexia , nausea , early satiety. 
6. Right upper abdominal pain. 
7. Confusion , disorientation. 
Signs(75): 
1. Pedal edema 
2. S3 gallop, S4 
3. Cardiomegaly  
4. Elevated jugular venous pulse 
5. Fine crackles 
6. Pleural effusion (usually bilateral , sometimes right sided) 
7. Hepatomegaly   
8. Ascites 
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Diagnosis: 
Clinical features may suggest heart failure but 2D echocardiogram 
with doppler is essential for assessing the left ventricular function. Chest 
x-ray is essential for assessing the pulmonary vasculature and heart size. 
ANP and N-terminal pro-BNP levels(75) are elevated in heart 
failure. But they are also elevated in old age, renal failure , obesity and 
pregnancy. So they act as adjuncts. Troponin levels will indicate 
myocardial cell necrosis(76).  
ECG is needed to know the presence of any infarctions, rhythm 
abnormalities.  
Routine investigations like CBC, urine routine examination, Blood 
urea, creatinine, Lipid profile, Thyroid profile should be taken.  
 
Differential diagnosis: 
1. Renal failure 
2. Acute respiratory distress syndrome 
3. Cirrhosis liver 
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MANAGEMENT OF CHF: 
FIGURE: 
 
 
ICD- Implantable Cardiac Defibrillator 
CRT-Cardiac Resynchronisation Therapy 
ARB-Angiotensin Receptor Blocker 
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ACE- inhibitors in CCF therapy: 
FIGURE: 
 
ACE inhibitors play a main role in reducing the ventricular 
remodeling and thereby improving the survival. But the main adverse 
effects of ACE inhibitors are dry cough , angioedema and hyperkalemia. 
It is due to decreased degradation of bradykinin. In case of dry cough 
shifting to ARB’s will avoid it since kinin degradation is not altered(77). 
 
Diuretics : 
They reduce the salt and water retention and thereby prevent the 
volume overload. Congestive features will be alleviated with the use of 
diuretics. Loop diuretics are preferred generally because of their efficacy. 
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The main adverse effect of loop diuretics is hypokalemia. It can be 
avoided by using potassium sparing diuretics like Spironolactone. 
The use of aldosterone antagonist is preferred in case of NYHA 3 
or 4,very poor EF(<30) and patient is already taking diuretics, ACE 
inhibitors and beta blockers(78). 
DIGOXIN: 
The use of digoxin in CHF is preferred in symptomatic patients 
with Atrial fibrillation(79).  
 
CARDIAC RESYNCHRONISATION THERAPY: 
It is indicated in symptomatic heart failure with Ejection Fraction 
less than 35% and duration of the QRS complex in ECG more than 120 
msec. This device will stimulate the ventricles simultaneously and 
improve the ejection fraction(80). 
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PRECIPITANTS OF ACUTE DECOMPENSATION OF CCF: 
 
Anemia 
Myocardial ischemia/infarction 
Infection 
Poor compliance 
Alcohol consumption 
Dietary indiscretion 
 
 
 
Initiation of medications that worsen HF 
  Calcium antagonists (verapamil, diltiazem) 
  Beta blockers 
  NSAIDS 
  Antiarrhythmic agents [all class I agents, sotalol (class III)] 
  Anti-TNF antibodies 
Arrhythmias 
Pregnancy 
Uncontrolled hypertension 
Acute regurgitant lesions 
 
There are various tell tale evidence of past myocardial injury in an 
resting 12 lead ECG,such as Q waves,wide QRS with bundle branch 
block and persistent ST elevation.Very little known entity is fragmented 
QRS complexes (fQRS). 
 An fQRS is defined by the presence of additional of R wave (R’) 
or notching in the nadir of the S wave or the presence of  >1 R’ in two 
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contiguous leads(81). 
 
 
 
This may be the only electrocardiographic marker of myocardial 
injury in non ST elevation MI and resolved Q wave.It may be a marker of 
left ventricular function. 
Fragmentation in ECG is due to dysynchronous excitation of 
myofibres due to poorly interconnected muscle fibres;divided by high 
resistance intercellular connective tissue developed by myocardial 
scarring(82).Chamber dilatation and other gross structural abnormalities 
may show a similar pattern. 
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Fragmented QRS and left ventricular function 
fQRS in an ECG independently predicts the left ventricular 
ejection fraction.This is a marker of high stress myocardial perfusion 
abnormalities.It was found in other studies that chamber dilatation 
grossly and decreased ejection fraction is truly reflected by 
fragmentation(83). 
 
Prognosis with fragmented QRS 
Fragmented QRS along with presence or absence of Q waves 
predict recurrent cardiac events and higher mortality.Though fQRS is not 
studied extensively is a reliable indicator of past ischemia of myocardium 
in the absence of Q wave(84).This suggests poorer prognosis because of 
the increased scar burden. 
 
fQRS in non coronary artery diseases 
Fragmentation is associated with other non coronary diseases like 
dilated cardiomyopathy,cardiac sarcoidosis,Brugada syndrome,acquired 
long QT syndrome(85). 
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Limitations of fQRS 
To produce an fragmentation requires low pass filters settings(100 
or 150 Hz)..It may be missed in filter setting of 40 or 60 Hz .Fragmented 
QRS is a non specific finding and should be interpreted only with 
evidence of CAD or myocardial scar(86). 
 
Mustafa Cetin et al 2012 done a study on relationship between 
fQRS  and systemic inflammation and found that fQRS was associated 
with increased CRP,left ventricular dysfunction and QRS duration.In 
addition ,fQRS also related with increased risk of cardiac risk with stable 
CAD patients.  
 
V.M. Alla et al done a study on relationship between prognosis of 
patients with non ischemic cardiomyopathy and presence offQRS in their 
ECGs.It was found that the patients with narrow QRS and non ischemic 
cardiomyopathy the presence offQRS in ECG doesn’t predict recurrent 
admissions for heart failure and all cause mortality. 
Luc Lorgis, MD, PhD et al done a study on patients with acute 
myocardial infarction with presence of fQRS and its prognosticative 
value.He found that the there was a decreased survival rate in patients 
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with persistent fQRS and also recurrent myocardial infarction in patients 
with transient fQRS. 
ErsinYıldırım et al in 2013 done a study in Acute STEMI Patients 
on the the presence of fQRS derivations and the number of fQRS 
derivations is associated with increasing size of infarction. 
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AIM OF THE STUDY: 
1) To study the association between fQRS complexes in ECG and 
Left Ventricular Ejection Fraction and 
2) To assess the usefulness of fQRS in determining the possibility of 
occurrence of adverse cardiac events (Ventricular tachycardia/fibrillation 
and sudden cardiac death) in Acute ST-elevation Myocardial Infarction. 
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BACKGROUND 
SELECTION OF SUBJECTS: 
 Patients who were admitted in the intensive coronary care unit, 
Kilpauk Medical College Hospital. 
           Patients with fQRS were enrolled in cases.Patients without fQRS 
were enrolled in controls. 
INCLUSION CRITERIA: 
Patients presenting with acute ST elevation MI (STEMI)within 48 hoursof 
onset of symptoms. 
 
EXCLUSION CRITERIA: 
Patients with 
 known Coronary artery disease 
 known heart failure 
 with typical RBBB/LBBB pattern in admission ECG. 
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MATERIALS AND METHODS 
SETTING:  
Kilpauk Medical College Hospital 
STUDY DESIGN:  
Case Control study                                                                                       
PERIOD OF STUDY:  
6 months 
SAMPLE SIZE:  
          60 subjects (30 cases+30 controls) 
ETHICAL CLEARANCE:  
Necessary ethical clearance was obtained from ethical committee, 
Kilpauk Medical College &Hospital, Chennai. 
 
COLLABORATING DEPARTMENT: 
Department of Cardiology, Kilpauk Medical College &Hospital, 
Chennai. 
 
SAMPLE SIZE AND SAMPLING METHOD: 
Consecutive patients of MI satisfying the inclusion criteria will be 
included. Assuming mean  left ventricular ejection fraction in MI patients 
with fQRS and MI patients without  fQRS as   41.66 % (SD: ±11.45) and 
50.21% (SD:± 10.47) respectively, alpha error of 5% and 90% power, 30 
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MI patients with fQRS and 30 MI patients without fQRS will be required 
for the study (OpenEpi software). 
 
 
  
 
 
DATA COLLECTION: 
The data of each patientswas collected in a specifically prepared 
proforma and includes relevant medical history, ECG findings on 
Admission and serial ECGs, and ejection fraction assessed by 
Echocardiogram within 48 hours of onset of symptoms. 
 
STATISTICAL METHODS: 
 
Data were  entered in Microsoft Excel spreadsheet and analysed in 
SPSS software. Continuous variables like age and ejection fraction were 
expressed as mean (Standard Deviation). Association between fQRS and 
Ejection fraction was tested by comparing ejection fraction  in Acute MI 
73 
 
patients having fQRS(cases)  with that of Acute MI patients not having 
fQRS(controls),by Univariate analysis , done with paired t test and 
Pearson product moment correlation coefficient. A chi squared test was 
used to analyze the probability of differences in frequency distributions 
between the groups and p<0.05 was taken to be statistically significant in 
all calculations. 
Occurrence of adverse cardiac events(ventricular 
tachycardia/ventricular fibrillation,sudden cardiac death)  following  
Acute MI among the two groups will be expressed as percentages. 
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DATA  ANALYSIS 
                  The results of the study are shown in tables as below. The 
baseline characteristics observed are as follows, 
Number of cases studied are-60. 
SEX  DISTRIBUTION 
 
  
 
 
  GROUP TOTAL 
  CONTROL CASES  
 
 
 
 
 
 
 
 
SEX 
 
 
 
 
 
 
 
 
MALE 
 
 
COUNT 23 22 45 
% WITHIN 
SEX 51.1% 48.9% 100.0% 
% WITHIN 
GROUP 76.7% 73.3% 75.0% 
 
 
 
 
FEMALE 
 
 
COUNT 
7 8 15 
% WITHIN 
SEX 46.7% 53.3% 100.0% 
% WITHIN 
GROUP 23.3% 26.7% 25.0% 
 
TOTAL 
 
 
 
COUNT 
30 30 60 
Table 1 
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Fig 1 
 
In this study the total no of males contribute 75% .females 25%. In 
cases males are higher 22%,females 8%. In controls females are 7%, 
males 23%. The P value is 0.766.So there is no significant difference in 
sex group in cases and controls. 
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DM  GROUP 
Table 2 
The diabetic patients in this study group is 65 %.In cases 63.3% 
and in controls 66.7%.The p value is 0.787.So the difference in diabetes 
population between cases and control are not significant. 
      The above finding is shown in the following graph 
 
 
 
 
 
 GROUP Total 
CASES CONTROLS 
DM 
Count 19 20 39 
% of Total 63.3% 66.7% 65% 
Non-DM 
Count 11 10 21 
% of Total 36.7% 33.3% 35% 
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Fig 2 
 
HYPERTENSION GROUP 
In this study hypertensive population is 71.7%.Percentage of SHT 
in cases 66.7%.Percentage of SHT in  controls 76.7%.The p value is 
0.390.So there is no significant difference between two groups.The above 
finding is shown in the following table 
 
 
 
Dm
NoYes
C
ou
nt
22
20
18
16
14
12
10
8
Group
Control
Cases
78 
 
                                                         Table 3 
 
 GROUP Total 
CASES CONTROLS 
 
SHT 
Count 20 23 43 
% of Total 66.7% 76.7% 71.7% 
Non-
SHT 
Count 10 7 17 
% of Total 33.3% 23.3% 28.3% 
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Fig 3 
SMOKING GROUP 
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 Table 4 
 
 
In this study smoking population is 50%.Percentage of smokers in 
cases 50%.Percentage of SHT in  controls 50%.The p value is 0.606.So 
there is no significant difference between two groups.The  finding are 
shown in the following above  table. 
 
 
 
 
 
 
 
 GROUP Total 
CASES CONTROLS 
 
SMOKERS 
Count 16 14 30 
% of Total 53.3% 46.7% 50% 
Non-
SMOKERS 
Count 14 16 30 
% of Total 53.3% 46.7% 50% 
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ALCOHOL GROUP 
Table 5 
 
 GROUP Total 
   CASES CONTROLS 
 
ALCOHOLIC 
Count 16         15 31 
% of Total 53.3 % 50% 51.7% 
Non 
ALCOHOLIC 
Count 14 15 29 
% of Total 46.7% 50% 48.3% 
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                                                FIG 5 
In this study alcoholic  population is 51.7 %.Percentage of 
alcoholics in cases 53.3%.Percentage of alcoholics in  controls 50%.The 
p value is 0.796.So there is no significant difference between two 
groups.The  finding are shown in the following table 5. 
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DISTRIBUTION OF VARIOUS TYPE OF MI IN STUDY 
POPULATION 
  Group 
Total 
   Control Cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type of MI 
 
 
AWMI 
Count 
17 21 38 
% within Type of 
MI 44.7% 55.3% 100.0% 
% within Group 
56.7% 70.0% 63.3% 
 
 
 
IWMI 
Count 
10 7 17 
% within Type of 
MI 58.8% 41.2% 100.0% 
% within Group 
33.3% 23.3% 28.3% 
 
 
 
LWMI 
Count 
2 1 3 
% within Type of 
MI 66.7% 33.3% 100.0% 
% within Group 
6.7% 3.3% 5.0% 
 
 
 
ASMI 
Count 
0 1 1 
% within Type of 
MI .0% 100.0% 100.0% 
% within Group 
.0% 3.3% 1.7% 
 
 
 
RWMI 
Count 
1 0 1 
% within Type of 
MI 100.0% .0% 100.0% 
% within Group 
3.3% .0% 1.7% 
 
 
Total 
Count 
30 30 60 
% within Type of 
MI 50.0% 50.0% 100.0% 
% within Group 
100.0% 100.0% 100.0% 
TABLE 6 
84 
 
Type of Mi
RWMIASMILWMIIWMIAWMI
C
ou
nt
30
20
10
0
Group
Control
Cases
 
 
FIG 6 
 
 
 
The above table shows the distribution of various type of 
myocardial infarction among the cases and controls.Among the cases 
anterior wall MI,inferior wall MI,lateral wall MI,anteroseptal MI and 
right ventricular wall MI comprises of 70.7% ,23.3% ,3.3% ,3.3% and 
0.0% respectively. 
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Among the controls anterior wall MI,inferior wall MI,lateral wall 
MI,anteroseptal MI and right ventricular wall MI comprises of 56.7% 
,33.3% ,6.7% ,0.0% and 3.3% respectively. 
The p value is 0.512.Hence there is no statistical difference 
between the distribution of various type of myocardial infarction among 
the cases and controls. 
          Hence the occurrence of fragmented QRS in acute ST elevation MI 
is not dependent upon the type of the myocardial infarction. 
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Type of 
MI Control Cases 
IWMI 10 7 
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Type of 
MI Control Cases 
ASMI 0 1 
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Type of 
MI Control Cases 
RWMI 1 0 
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DISTRIBUTION OF FRAGEMENTED QRS 
 
  
Group 
Total Control Cases 
 
 
 
 
 
 
 
 
 
Fragmented 
QRS 
 
 
 
 
Yes 
 
Count 0 30 30 
 
% 
 within 
Fragmented 
QRS 
.0% 100.0% 100.0% 
 
% within Group .0% 100.0% 50.0% 
 
 
 
No 
 
Count 30 0 30 
 
% within 
Fragmented 
QRS 100.0% .0% 100.0% 
 
% within Group 100.0% .0% 50.0% 
 
 
 
Total 
 
Count 30 30 60 
 
% within 
Fragmented 
QRS 50.0% 50.0% 100.0% 
 
% within Group 100.0% 100.0% 100.0% 
 
                                                TABLE 7 
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FIG  7 
 
The p value is < 0.001**.Since this is a case control study the and 
the patients with fragmented QRS are enrolled under cases and patients 
without fragmented QRS are enrolled under controls there are equal 
number of cases and controls. 
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VENTRICULAR TACHYCARDIA/FIBRILLATION 
DISTRIBUTION 
 
  
Group 
Total Control Cases 
 
 
 
 
 
 
 
 
Ventricular 
Tachycardia/Fibrillation 
 
 
 
 
Yes 
 
Count 1 2 3 
 
% within Ventricular 
Tachycardia/Fibrillation 33.3% 66.7% 100.0% 
 
% within Group 3.3% 6.7% 5.0% 
 
 
 
No 
 
Count 29 28 57 
 
% within Ventricular 
Tachycardia/Fibrillation 50.9% 49.1% 100.0% 
 
% within Group 96.7% 93.3% 95.0% 
 
 
 
 
 
Total 
 
Count 30 30 60 
 
% within Ventricular 
Tachycardia/Fibrillation 50.0% 50.0% 100.0% 
 
% within Group 100.0% 100.0% 100.0% 
TABLE 8 
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FIG 8 
 
 Among various studies conducted there was a significant 
statistical difference in occurrence of adverse cardiac events like 
ventricular tachycardia ,ventricular fibrillation or sudden cardiac 
death.But in this study p value is 0.554.Hence there is no statistical 
difference between two groups. 
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GROUP STATISTICS 
AGE  
 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
 
 
 
Age in years 
 
Control 30 56.43 13.518 2.468 
 
Cases 30 54.43 11.578 2.114 
 
                                            TABLE 8 
 
Age distribution among the cases and controls.Mean age among 
the cases  54.43.Mean age among the controls is 56.43. 
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SYSTOLIC BP AND DIASTOLIC BP 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
 
 
SBP 
 
Control 30 132.67 29.704 5.423 
 
Cases 30 133.67 23.265 4.248 
 
 
DBP 
 
Control 30 84.00 14.994 2.738 
 
Cases 30 86.33 12.994 2.372 
                                                            TABLE 9 
 
 
Systolic BP  and diastolic BP among the cases are 133.67 and 
86.33 respectively. Systolic BP  and diastolic BP among the controls are 
132.67 and 84.00 respectively. 
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DESCRIPTIVE STATISTICS 
 
 N Minimum Maximum Mean Std. Deviation 
 
Age in years 60 22 85 55.43 12.519 
 
SBP 60 80 220 133.17 26.457 
 
DBP 60 60 120 85.17 13.960 
 
Ejection Fraction 
60 24.65 70.11 47.5092 13.12034 
 
                                                        TABLE 10 
 The above table 10 shows the minimum age recorded in the study 
is 22 and maximum is 85.The minimum and maximum systolic BP are 80 
and 220 mm of Hg respectively.The minimum and maximum systolic BP 
are 60 and 120 mm of Hg  respectively. The minimum and maximum 
ejection fraction are 24.65 and 70.11 %  respectively.  
 
RELATIONSHIP BETWEEN FRAGMENTED QRS AND LEFT 
VENTRICULAR EJECTION FRACTION 
 
 Fragmented QRS N Mean Std. Deviation P value 
 
 
Ejection Fraction 
 
Yes 30 40.9510 11.18528 
<0.001**  
No 30 54.0673 11.66733 
 
                                            TABLE 11 
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Table 11 shows the relationship between the fragmented QRS and 
left ventricular ejection fraction.p value is < 0.001**. Hence there is an 
statistically difference between the cases and controls. 
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DISCUSSION 
Ischemic heart disease is leading as  the important cause of 
morbidity and mortality in India as well as in developing countries. Acute 
coronary syndrome  (ST elevation MI,Non ST elevation MI,Unstable 
angina)is a medical emergency. There is a  high prevalence of risk factors 
likediabetes mellitus, alcoholism smoking, hypertension, together with 
adverse life style changes, incidence  of acute coronary syndrome is 
increasing day by day. 
Prognosis in patients with acute coronary syndrome can be 
assessed by number of factors like associated heart  failure signs,left 
ventricular ejection fraction, raised  cardiac biomarkers.  
In this  case control study of relationship between fragmented QRS  
in an ECG and left ventricular ejection fraction  patients presenting with 
Acute ST elevation MI consists of a group of 60 patients(cases 
30+controls 30) who were admitted in intensive coronary care unit, 
Kilpauk Medical College &Hospital, Chennai. 
A total of 30 cases were taken into the study.Cases are the patients 
with presence of fragmented QRS in the ECG .Controls were 30 in 
number.Controls are patients who were not having fragmented QRS in 
the ECG. 
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SEX DISTRIBUTION 
In both cases and control group males were predominating .This 
may be attributed to life style activities like smoking and alcoholism. 
 
EJECTION FRACTION AND FRAGMENTED QRS 
Study showed that the mean ejection fraction of the cases group is 
40.95 %.Mean ejection fraction fraction of the control group is 54.06 %.p 
value is < 0.001**.So there is significant statistical relationship between 
the presence of fragmented QRS and the ejection fraction. 
 
VENTRICULAR TACHYCARDIA/FIBRILLATION AND 
FRAGMENTED QRS 
Study showed that there is no statistical difference in occurrence of 
ventricular tachycardia/fibrillation among cases and controls.p value is 
0.554. 
 
Study done by  Mr. Wang et al. in 2010 failed to show significant 
relationship  for fQRSin detection of myocardial scarring in patients with 
coronary artery disease. 
Since fQRS represents myocardial scarring, fQRS may be 
associated with ventricular tachyarrythmiaand heart failure 
 
99 
 
In 2012  Torigoe et al done a study and evaluated that the 
fragmented QRS by 12-lead ECG and showed that the number of the 
leads with fragmented QRS was a predictor for cardiac related death and 
recurrent hospitalization for cardiac failure in patients with prior 
myocardial infarction. Although the positive fragmented QRS is defined 
by the criteria included the presence of fQRS in two or more 
corresponding leads, study  showed that the presence of fragmented QRS 
in three or more leads was the most useful for differentiating  between  
the patients with and without risk for  sudden cardiac death or repeated 
hospitalization for cardiac failure. 
Presence of fragmented QRS  in an 12 lead ECG signifies 
distortion of  depolarization process and signal conduction  within the 
ventricular musculature, and  is related to myocardial scarring or 
myocardial fibrosis. 
Previous papers published  on patients with stable coronary artery 
disease  or myocardial infarction have provided  data consistent  that 
fQRS is frequent, and is a reliable and simple tool to predict adverse 
cardiac events and all cause mortality.  
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CONCLUSION 
 
 
1) There is an significant association between presence of fragmented 
QRS and the ejection fraction in the setting acute ST elevation 
myocardial infarction 
 
2) There is no significant statistical relationship between presence of 
fragmented  QRS and occurrence of ventricular tachycardia/fibrillation,in 
contrast to previous studies.This may be attributed the smaller sample 
size. 
 
3)This study shows no statistically significant relationship between 
presence or absence of fragmented QRS   and sex distribution, diabetes, 
hypertension and alcoholism. 
 
4)There has been a retrospective study done which shows thatif the 
patient has a preexisting fQRS complex on the ECG and a implantable 
cardioverterdefibrillator (ICD), the device is more likely to 
discharge(87).Hence in the future, it may become a tool in the selection of 
appropriate candidates for ICD implantation. 
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LIMITATIONS OF THE STUDY 
 Fragmented QRS in a 12 lead ECG requires an optimal and low pass 
filter setting of 100 or 150 Hz. Fragmentation may beeasily  missed with 
using of  a filter setting of 40 or 60 Hz. 
 
 It should be kept in mind that fragmented QRS is  not a specific finding 
and should only be interpreted only in the presence of appropriate clinical 
evidence of myocardial scarring as in coronary artery disease or primary 
electrical abnormalities such as Brugada syndrome. 
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ABBREVIATIONS USED 
ACS- ACUTE CORONARY SYNDROME 
STEMI- ST ELEVATION MYOCARDIAL INFARCTION.  
NSTEMI- NON ST ELEVATION MYOCARDIAL INFARCTION 
UA- UNSTABLE ANGINA 
SHT- SYSTEMIC HYPERTENSION 
DM- DIABETES MELLITUS 
LVD- LEFT VENTRICULAR DYSFUNCTION 
AWMI- ANTERIOR WALL MYOCARDIAL INFARCTION 
IWMI- INFERIOR WALL MYOCARDIAL INFARCTION 
RVMI- RIGHT VENTRICULAR MYOCARDIAL INFARCTION 
CPK-MB- CREATININE PHOSPHOKINASE MB 
B-BLOCKER- BETA BLOCKER 
CHD- CORONARY HEART DISEASE 
ACE- ANGOTENSION CONVERTING ENZYME 
PCI- PERCUTANEOUS CORONARY INTREVENTION 
ECG- ELECTROCARDIOGRAM 
HDL-HIGH DENSUTY LIPOPROTEIN 
LDL- LOW DENSITY LIPOPROTEIN 
SMC- SMOOTH MUSCLE CELL 
UFH- UNFRACTIONATED HEPARIN 
LMWH- LOW MOLECULAR WEIGHT HEPARIN 
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PROFORMA 
 
NAME:                                                                            AGE/SEX:                                    
I.P.NO: 
 
ADDRESS : 
 
OCCUPATION : 
RISK FACTORS  
                              SYSTEMIC HYPERTENSION               Y/N  
                              DIABETES MELLITUS                          Y/N  
                              SMOKING                                               Y/N  
                              ALCOHOLISM                                        Y/N  
 
DATE AND TIME OF ONSET OF SYMPTOMS : 
 
DATE AND TIME OF ADMISSION  : 
 
DATE OF DISCHARGE    : 
 
ELECTROCARDIOGRAPHIC (ECG) FINDINGS  : 
 
ECHOCARDIOGRAM FINDINGS  : 
 
EJECTION FRACTION    : 
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   MASTER CHART-CASES 
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    MASTER CHART-CONTROLS 
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